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Abstract
Background
Cryptococcal meningitis (CCM) remains a leading cause of mortality amongst HIV infected
patients in sub-Saharan Africa. When patients receive recommended therapy, mortality at
10 weeks has been reported to vary between 20 to 36%. However, mortality rate and factors
affecting mortality after completing recommended therapy are not well known. We investi-
gated mortality rate, and factors affecting mortality at 2 years among CCM patients following
completion of recommended CCM therapy in Uganda.
Methods
A retrospective cohort study was conducted among HIV infected patients that had com-
pleted 10 weeks of recommended therapy for CCM (2 weeks of intravenous amphotericin B
1mg/kg and 10 weeks of oral Fluconazole 800mg daily) in the CryptoDex trial
(ISRCTN59144167) between 2013 and 2015. Survival analysis applying Cox regression
was used to determine the mortality rate and factors affecting mortality at 2 years.
Results
This study followed up 112 participants for 2 years. Mean age (±SD) was 34.9 ± 8, 48
(57.1%) were female and 80 (74.8%) had been on ART for less than 1 year. At 2 years, over-
all mortality was 30.9% (20 deaths per 100 person-years). Majority of deaths (61.8%)
occurred during the first 6 months. In multivariable analysis, mortality was associated with
ever being re-admitted since discharge after hospital-based management of CCM (aHR =
13.33, 95% CI: 5.92–30.03), p<0.001; and self-perceived quality of life, with quality of life
50–75% having reduced risk compared to <50% (aHR = 0.21, 95% CI: 0.09–0.5), p<0.001,
as well as >75% compared to <50% (HR = 0.29, 95% CI: 0.11–0.81), p = 0.018.
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Conclusion
There remains a considerable risk of mortality in the first two years after completion of stan-
dard therapy for CCM in resource-limited settings with risk highest during the first 6 months.
Maintenance of patient follow up during this period may reduce mortality.
Introduction
Mortality from HIV related opportunistic infections remains high especially in sub-Saharan
Africa despite widespread antiretroviral therapy (ART) use [1]. Cryptococcal meningitis
(CCM) is one of the leading contributors, killing as many as 70% of infected people especially
in settings where treatment is inadequate [1–3]. In 2014, 162,500 cases of CCM were estimated
to occur in sub-Saharan Africa annually, leading to 135,900 deaths [1]. Uganda ranked fourth
on incidence in the region with 12,200 cases estimated to occur annually, only lower than
Nigeria (27,100 cases), South Africa (21,400 cases) and Mozambique (18,600 cases). One of the
reasons for the high mortality in CCM in low resource countries including Uganda is that
majority of the patients are treated with suboptimal regimens, in most cases using varying
doses of Fluconazole [4]. However, even when treated with optimal regimens (Amphotericin
based therapy), mortality in these settings has remained high, varying between 20% and 36%
at 10 weeks due to a number of reasons such as elevated intracranial pressure, inadequate fun-
gal clearance and drug-related toxicities [5–7].
Little is known about the mortality rate and factors affecting mortality after completion of
standard treatment for CCM. These patients remain debilitated by complications such as
visual and hearing impairment, movement abnormalities and convulsions, among others.
They also remain at risk of CCM relapse and immune reconstitution syndrome (IRIS) [7,8].
These may cause the risk of mortality to remain. Here, we present results of a study conducted
to determine the mortality rate and factors affecting mortality among patients that had com-
pleted 10 weeks of treatment for CCM in Uganda.
Methodology
Study design and setting
This was a retrospective cohort study conducted among patients that had completed 10 weeks
of treatment for CCM in Uganda in a previous trial—the CryptoDex trial (Clinical trials regis-
tration number ISRCTN59144167) [9]. The CryptoDex trial was a double-blind placebo-con-
trolled phase III trial of adjunctive dexamethasone in HIV infected adults with Cryptococcal
meningitis. The trial was conducted at six sites in Asia and Africa including two sites in
Uganda between 2013 and 2015. The Ugandan sites were located at the Medical Research
Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medi-
cine Uganda Research Unit (MRC/UVRI & LSHTM Uganda Research Unit) clinics, in Masaka
and Entebbe towns. Entebbe and Masaka are located 37 and 140 kilometres respectively south-
west of Kampala city. Patients enrolled from Masaka were admitted to Masaka Regional Refer-
ral Hospital and mainly originated from rural settings that make up the hospital catchment
area. Patients enrolled at Entebbe were admitted to Entebbe General Hospital and originated
from semi-urban settings that serve as the catchment area for the hospital. Both hospitals are
public facilities. This study only collected information on patients previously managed in
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Uganda partly because of resource constraints but also because this country represents the
highest burden of CCM among those involved in the CryptoDex study.
Patients enrolled in the CryptoDex trial and their management
Patients recruited in the CryptoDex trial were 18 years and above, had a clinical syndrome
consistent with HIV associated CCM, and microbiologically confirmed disease as indicated by
one or more of the following test results: positive India ink staining of cerebral spinal fluid
(CSF); culture of Cryptococcal species from CSF or blood; or Cryptococcal antigen detected in
CSF on Cryptococcal antigen lateral flow assay. They were randomised to receive either dexa-
methasone adjunctive therapy or placebo in a tapered dose up to 42 days post randomisation.
All patients were treated with intravenous Amphotericin B (1mg/kg/day) and 800mg daily oral
Fluconazole for 14 days (induction phase), followed by 800mg daily Fluconazole (continuation
phase) to complete 10 weeks of treatment. After 10 weeks, all patients were switched to 200mg
daily Fluconazole (Maintenance phase). This regimen is recommended by WHO for settings
where Flucytosine is not available to be used during the induction period [10].
Study subjects and sampling for the two-year post CCM treatment study
The two-year post CCM treatment study was conducted between May 2017 and July 2017
(data collection), and collected information on participants that had survived up to 10 weeks
in the CryptoDex trial, and therefore completed 10 weeks of treatment. Participants whose sur-
vival status could not be determined for at least one time point after completion of treatment
in the CryptoDex trial were ineligible. Following this eligibility criterion, all 112 participants
that completed 10 weeks in the CryptoDex trial qualified to participate in this study and were
recruited.
Data collection
Data was collected using semi-structured questionnaires, which were developed in English,
translated to Luganda and back-translated. These were standardised and initially piloted prior
to use in this study to assess comprehensibility. Four trained research assistants administered
the questionnaires. Information from participants who died after 10 weeks in the study was
acquired through a next of kin while living participants were contacted in person. Participants
were traced using contact details previously collected while in the CryptoDex trial. One session
was organised with the participant or next of kin during which an interview was administered
while other required information was retrieved from the CryptoDex trial database.
Variables and their measurement
The dependent variable was time to death measured from the date a participant completed 10
weeks in the CryptoDex trial. Independent variables included demographic characteristics
(age, sex, marital status, education); site i.e. Masaka (rural) or Entebbe (semi-urban); quality of
life at completion of week 10 in the CryptoDex trial (measured using the EQ VAS scale of the
EQ-5D-3L tool [11], presented as a percentage of self-perceived quality of life relative to full
health); antiretroviral therapy (ART) use at treatment completion (on ART or not on ART);
readmission status (ever readmitted or never readmitted, i.e., a patient was discharged when
stable after completing intravenous therapy in the CryptoDex trial, this variable referring to
re-admission that occurred between discharge from hospital and completion of 10 weeks of
therapy); and randomisation status as received dexamethasone or not. Other information col-
lected included the date of completion of 10 weeks in the CryptoDex trial, location where
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participant died and most likely cause of death based on a verbal autopsy (conducted using a
tool adapted from the COSTOP trial [12]) complemented by information from patient records
where accessible.
Data analysis
Data was entered into a Microsoft Access database, cleaned and exported to STATA (College
Station, TX, version 13.0). Descriptive statistics were presented in form of frequencies and per-
centages for categorical variables while continuous variables were summarised using means
(standard deviation) and/or medians (interquartile ranges).
Data was then converted into survival format, i.e., time-to-event data. The date the partici-
pant completed 10 weeks of treatment for CCM served as time zero/entry time while censoring
was done at the time a participant completed 2 years from entry or the time last seen for those
we could not trace. Time accrued was measured in person-years estimated as the difference in
time from entry to death or time of censor. A Kaplan-Meier (K-M) graph was computed for
the cohort to demonstrate the survival trend over the two years. The life table method was
used to compute the proportion surviving at different intervals of time. Overall mortality rate
was determined, followed by mortality stratified by participant characteristics. Bivariate analy-
sis was done to determine crude associations between mortality and participant characteristics
by fitting Cox regression models. Variables that had a p-value of 0.2 and below at bivariate
analysis were used in building a multivariable Cox regression model using a stepwise
approach. Age and Sex were tested in the model irrespective of their p-value at bivariable anal-
ysis. The proportional hazards assumption was tested for all variables used in the final model.
The same variables were also tested for inter-associations using logistic regression. In the final
model, all variables with a p-value of 0.05 and below were considered statistically significant.
Results are reported as hazard ratios (HR) and their 95% confidence intervals (CI).
Ethical considerations
The study was approved by the Makerere University School of Public Health Research and
Ethics Committee. Permission to use information from the CryptoDex database was acquired
following standard MRC/UVRI & LSHTM Uganda Research Unit data sharing policy available
at https://www.mrcuganda.org/publications/data-sharing-policy. Written informed consent
was obtained from all participants prior to data collection. For participants that had died, a
next of kin provided consent.
Results
Baseline characteristics
Of the 212 participants enrolled in the CryptoDex trial in Uganda, 100 died while 112 com-
pleted 10 weeks of therapy. All 112 participants that had completed treatment were found eligi-
ble for this study and were included (Fig 1). Forty-two (37.5%) of these had been managed at
the Entebbe site and 70 (62.5%) at the Masaka site. The mean age (±SD) of participants was
34.9 ± 8 years and 56 (50%) were between 30–40 years. Sixty-four (57.1%) of the participants
were female and 104 (92.9%) had attained at least primary level education. The median dura-
tion since HIV diagnosis was 0.8 years (IQR 0.3, 2.8), with 61 (54.5%) diagnosed within one
year prior to completion of CCM treatment. The median duration on ART at baseline was 3.3
months (IQR 1.2, 11.1) with 80 of 107 (74.8%) having been on ART for less than 1 year.
Thirty-five participants (31.2%) rated their baseline quality of life to be above 75%, while 60
(53.6%) were between 50–75%. Eighty-one participants (73.6%) had not been re-admitted
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between the admission at CCM diagnosis and completion of therapy at 10 weeks. Details of
the baseline characteristics are shown in Table 1.
Mortality rate at 2 years
At 2 years following completion of treatment for CCM, 34 of the 112 participants (30.4%) had
died, giving an overall mortality rate of 20 deaths per 100 person-years after 172.7 person-
years of follow up. Fig 2 is a K-M plot showing the survival of the whole cohort in the two-year
period. The proportion surviving had reduced to 81.2% by 6 months and from there only
reduced to 70.2 at 24 months basing on the life-table (61.8% of all deaths occurred in the first 6
months). Fifty percent (17) of the deaths occurred at home and the rest at a health-care facility.
Of 28 participants for whom a probable cause of death could be established, eight had fea-
tures suggestive of either CCM relapse or IRIS, six died due to septicaemia, four due to
Fig 1. Flow diagram showing participants enrolled into current study from the CryptoDex trial. �All patients treated with
1ml/kg of intravenous amphotericin B for 2 weeks and 800mg of oral Fluconazole daily for 10 weeks. ��Participants last seen
before completion of 2 years.
https://doi.org/10.1371/journal.pone.0210287.g001
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dehydration and two due to Anaemia. Other causes of death included hypoglycaemia, renal
failure, cancer, Addisonian crisis and HIV wasting syndrome.
Factors affecting mortality
Table 2 shows the unadjusted and adjusted hazard ratios for the different factors evaluated. All
variables used in the final model met the proportional hazards assumption (p = 0.76 for site,
p = 0.9 and p = 0.68 for quality of life<50 compared with 50–75 and<50 compared to 75
+ respectively, and p = 0.13 for readmission status). At multivariable analysis, ever being re-
admitted after CCM management was associated with increased risk of mortality
(aHR = 13.33, 95% CI: 5.92–30.03), p<0.001. There was reduced risk of mortality comparing
quality of life 50–75% and<50% (aHR = 0.21, 95% CI: 0.09–0.5), p<0.001, as well as quality of
life >75% compared to<50% (HR = 0.29, 95% CI: 0.11–0.81), p = 0.018. There was no signifi-
cant relationship between any two of the three variables used in the final model, i.e., site, base-
line quality of life, and readmission status.
Table 1. Baseline characteristics of study participants at completion of Cryptococcal meningitis therapy.
Characteristics Category Frequency Percentage
Site Entebbe (Semi-urban) 42 37.5
Masaka (Rural) 70 62.5
Age in years <30 32 28.6
30–40 56 50.0
41+ 24 21.4
Sex Male 64 57.1
Female 48 42.9
Marital Status Married 51 45.5
Not Married 61 54.5
Education None 8 7.1
Primary 69 61.6
Post primary 35 31.3
Duration since HIV diagnosis (years) <1 61 54.5
1–5 25 22.3
>5 26 23.2
ART status at Baseline On ART 107 95.5
Not on ART 5 4.5
Duration on ART (months) <3 46 43.0
3–12 34 31.8
>12 27 25.2
Baseline quality of life (%) <50 17 15.2
50–75 60 53.6
75+ 35 31.2
Dexamethasone use Yes 49 43.8
No 63 56.2
Readmission status Ever readmitted 31 27.7
Never readmitted 81 72.3
Abbreviations: SD, standard deviation; IQR, interquartile range; ART, Antiretroviral therapy.
https://doi.org/10.1371/journal.pone.0210287.t001
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Discussion
Mortality in this cohort of patients that had completed recommended treatment for CCM was
high, most remarkably during the first six months. Most studies previously done on CCM
have evaluated mortality from the time of treatment initiation or diagnosis [5,13,14]. This
cohort of AIDS patients manifest higher mortality compared to AIDS patients with similar
immunological status in Uganda. In a study done amongst Ugandan AIDS patients without
cryptococcosis, the mortality rate was much lower at 3.68 and 2.75 per 100 person-years
among groups with CD4 between 50–99 and 100–149 cells/uL respectively [14]. High mortal-
ity was demonstrated in another study done by Butler. E et al, where out of 104 patients alive
at 10 weeks of CCM treatment, 30 had died approximately 22 months later, a proportionate
mortality of 29% [13]. The same study revealed that mortality considered from the time of
treatment initiation is highest during the first 6 months [13]. Since our study determined mor-
tality starting from the time of treatment completion (10 weeks), the six months spurn consid-
ered by Butler. E et al include close to 4 months of our first 6 months. These findings affirm
that the threat of mortality does not necessarily disappear at treatment completion, but extends
for some time. With majority of previous studies emphasising the need to identify means of
reducing mortality during the 10 weeks of treatment [15–19], this excludes the considerable
number of deaths that occur in the first 6 months after treatment completion.
Verbal autopsy suggested that many of the deaths were likely to be attributable to CCM
relapse or IRIS. IRIS has been reported to increase the risk of mortality among CCM patients
initiating ART. In a study done by Boulware D et al among CCM patients in Uganda, those
who developed IRIS were 2.5 times more likely to die than the rest of the cohort, with IRIS
occurring at a median of 8.8 weeks from ART initiation [20]. Majority of participants in our
study had been on ART for less than 3 months, a factor that could have increased their risk of
getting IRIS. Relapse could have resulted from non-continuation of or poor adherence to Flu-
conazole maintenance therapy since this is often unavailable in health facilities offering care to
HIV infected patients in Uganda given its high cost.
Fig 2. Kaplan-Meier plot showing survival of participants during two years of follow up after completion of
recommended therapy.
https://doi.org/10.1371/journal.pone.0210287.g002
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According to Tenforde M et al, the occurrence of Cryptococcal meningitis is an indication
of an unsuccessful HIV care cascade. They further suggest that lack of follow up of patients
after treatment for CCM may partly be responsible for the bad treatment outcomes observed
in resource-limited settings [7]. The presence of a hospital or health facility offering care and
treatment for CCM and completion of treatment thereof, may not guarantee survival thereaf-
ter. Some patients still go back to the same conditions where they came from prior to diagno-
sis, which may be characterised by inadequacies in the social-economic conditions and poor
health services. These may therefore remain at risk of unfavourable outcomes such as IRIS and
relapse [7,8] for several months after completion of standard therapy. Even those that go to
ART providing centres may not get the kind of care they would have required for their post-
CCM sequelae due to lack of adequate logistics and health worker skills, and this may eventu-
ally contribute to post-treatment mortality [7].
We found that low self-perceived quality of life was associated with higher mortality. The
EQ-VAS scale used in this study gave respondents the opportunity to determine their own
health status at that particular point relative to what one considered as their own ideal (100%).
Table 2. Mortality rates, bivariate and multivariate analysis showing factors affecting mortality.
Variable Categories Number of deaths/
Person-time at risk
Mortality rates (per
100pyrs)
Unadjusted Hazard
Ratios (95% CI)
P-value Adjusted Hazard
Ratios (95% CI)
P-
value��
Overall 34/172.7 20
Site Entebbe 16/61.8 26 1 1
Masaka 18//110.9 16 0.64 (0.33–1.25) 0.19 0.48(0.22–1.03) 0.06
Age (yrs.) <30 12/49.5 24 1
30–40 17/84.7 20 0.82 (0.39–1.72) 0.60
41+ 5/38.5 13 0.56 (0.20–1.58) 0.27
Sex Male 19/97.9 19 1
Female 15/74.8 20 1.03 (0.53–2.03) 0.92
Marital Status Married 18/72.7 25 1
Not Married 16/99.4 16 0.67 (0.34–1.32) 0.25
Duration since HIV+
diagnosis (yrs.)
<1 20/88.9 23 1
1–5 7/41.2 17 0.79 (0.33–1.87) 0.60
>5 7/42.6 16 0.75 (0.32–1.77) 0.51
ART status Pre-ART 1/4.4 23 1
On ART 33/168.2 20 0.67 (0.31–1.43) 0.29
Duration on ART
(months)
<3 14/75.1 19 1
3–12 14/49.0 29 1.47 (0.70–3.09) 0.31
>12 5/44.2 11 0.62 (0.22–1.72) 0.36
Baseline quality of life <50% 10/19.2 52 1 1
50–75% 14/93.3 15 0.28 (0.13–0.64) 0.002 0.21 (0.09–0.5) <0.001�
76+% 10/55.5 18 0.35 (0.14–0.83) 0.019 0.29 (0.11–0.81) 0.018�
Received dexamethasone No 21/91.3 23 1
Yes 13/81.3 16 0.69 (0.34–1.40) 0.30
Re-admission status Never
readmitted
12/145.7 8 1 1
Ever
readmitted
22/26.9 82 7.84 (3.84–16.05) <0.001 13.33 (5.92–30.04) <0.001�
Abbreviations: Pyrs, Person-years; CI, Confidence interval; ART, Antiretroviral therapy; HIV, Human immunodeficiency virus; yrs., years
� P-value clinically significant at the 5% level (in the adjusted model).
�� P-values represented are for variables that had a p-value <0.2 in bivariable analysis that were used in the final adjusted model.
https://doi.org/10.1371/journal.pone.0210287.t002
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According to Jeremy D et al, successful treatment of CCM depends not only on effective anti-
fungal therapy but also on successful management of complications [9]. Other studies have
also shown that CCM survivors remain with many disabilities [4,15]. These complications and
disabilities do not necessarily cease at treatment completion, but continue and compromise a
patient’s quality of life, thereby posing a risk to the patients’ life [21]. An effect of quality of life
on survival has been demonstrated elsewhere in a study done in the United States among HIV
infected patients [22]. Ever being re-admitted after hospitalisation for CCM management was
also a risk factor for mortality. This suggests that those ever re-admitted are another vulnerable
group that needs extra follow up to curb the risk of mortality. It is interesting to note that dexa-
methasone adjunctive therapy did not significantly affect mortality at 2 years among those that
had completed CCM therapy. In the CryptoDex trial, dexamethasone did not have an effect on
the risk of mortality at 10 weeks [23]. In addition to the reasons proposed in the CryptoDex
paper for this observation, we did not expect patients that had received dexamethasone to have
residual drug in their system, because approximately one month had elapsed between the last
dose of dexamethasone and completion of 10 weeks of therapy for CCM. This drug has a short
half-life of 1–5 hours.
Because this study used pre-collected data, information on some important variables such
as ART adherence and Fluconazole continuation status could not be established. It is known
that Fluconazole continuation reduces the risk of relapse which may have an effect on mortal-
ity [24]. However, it is important to appreciate that this information is not available yet at
treatment completion and therefore cannot inform the clinician’s decision to determine the
nature of follow up required. This study considered all-cause mortality. Exclusion of mortality
attributable to other causes could have given a better appreciation of the associations demon-
strated here, or revealed more associations we were not able to find. However, this being an
immunologically depleted group of patients, they are at risk of other opportunistic infections
and therefore follow up ought to look out for these as well. Lastly, we had a small sample size,
potentially limiting the number of variables that could be evaluated. However, we had a rea-
sonable number of outcomes to do a modest multivariable analysis. This study did well to fol-
low up a cohort of patients that have previously not received a lot of attention. These are
patients that everyone would have expected to be well since they had completed recommended
treatment. To the contrary, we reveal that this remains a special group that may need more
than routine care. These findings are likely to be generalizable to HIV positive patients com-
pleting treatment for CCM in resource-limited settings.
This study reveals that patients that have completed treatment for CCM remain at risk of
mortality and therefore need follow up especially during the first six months. Patients that
have low quality of life (<50) and those that have ever been readmitted need to be more closely
followed up. HIV care facilities in sub-Saharan Africa need to be restructured so that they are
in position to offer specialised care for patients previously treated for CCM, a disease that car-
ries a huge burden of mortality during and after treatment.
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